FDA, Industry Call For Human Factors Approaches To Assuring Data Integrity
This article was originally published in The Gold Sheet
Human factors could be the key to data integrity. Agency and industry officials envision ways to stem the flow of data integrity warning letters and ensure data integrity by design with robust electronic production control systems and strong top-down cultural reforms.
You may also be interested in...
Lack of readiness derails eye drugs from Valeant and Ocular, which now must convince FDA they know what they are making; meanwhile, an expert shares how mistake-proofing processes can help.
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.